Health Care & Life Sciences » Pharmaceuticals | Eli Lilly & Co.

Eli Lilly & Co. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
23,113
19,616
19,959
21,222
22,871
24,556
Cost of Goods Sold (COGS) incl. D&A
4,908
4,933
5,037
5,655
6,070
6,430
Gross Income
18,205
14,683
14,922
15,567
16,801
18,126
SG&A Expense
12,657
11,354
11,329
11,696
11,870
11,939
EBIT
5,548
3,329
3,592
3,871
4,931
6,187
Unusual Expense
291
664
1,084
591
2,884
2,566
Non Operating Income/Expense
91
364
356
170
208
286
Interest Expense
160
149
161
185
225
272
Pretax Income
5,889
3,000
2,790
3,374
2,197
3,796
Income Tax
1,205
610
382
636
2,402
564
Consolidated Net Income
4,685
2,391
2,408
2,738
204
3,232
Net Income
4,685
2,391
2,408
2,738
204
3,232
Net Income After Extraordinaries
4,685
2,391
2,408
2,738
204
3,232
Net Income Available to Common
4,685
2,391
2,408
2,738
204
3,232
EPS (Basic)
4.32
2.23
2.26
2.58
0.19
3.13
Basic Shares Outstanding
1,081
1,070
1,062
1,058
1,052
1,028
EPS (Diluted)
4.32
2.23
2.26
2.58
0.19
3.13
Diluted Shares Outstanding
1,085
1,074
1,066
1,062
1,052
1,034
EBITDA
6,994
4,708
5,020
5,368
6,499
7,796
Non-Operating Interest Income
120
121
87
109
167
161

About Eli Lilly &

View Profile
Address
Lilly Corporate Center
Indianapolis Indiana 46285
United States
Employees -
Website http://www.lilly.com
Updated 07/08/2019
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. It operates through two segments: Human Pharmaceutical Products and Animal Health. The Human Pharmaceutical products segment includes the discovery, development, manufacturing, marketing and sales of human pharmaceutical products worldwide in the following therapeutic areas: neuroscience, endocrinology, oncology, cardiovascular and other.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.